Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Change in Inventory (2020 - 2025)

Historic Change in Inventory for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $4.1 million.

  • Xeris Biopharma Holdings' Change in Inventory rose 28979.01% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.4 million, marking a year-over-year increase of 16131.14%. This contributed to the annual value of $8.8 million for FY2024, which is 4067.82% down from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Change in Inventory of $4.1 million as of Q3 2025, which was up 28979.01% from $7.6 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Change in Inventory ranged from a high of $7.6 million in Q2 2025 and a low of $148000.0 during Q2 2022
  • Moreover, its 5-year median value for Change in Inventory was $2.3 million (2021), whereas its average is $2.8 million.
  • Per our database at Business Quant, Xeris Biopharma Holdings' Change in Inventory crashed by 9549.11% in 2022 and then soared by 492229.73% in 2023.
  • Quarter analysis of 5 years shows Xeris Biopharma Holdings' Change in Inventory stood at $2.3 million in 2021, then skyrocketed by 142.08% to $5.5 million in 2022, then tumbled by 74.55% to $1.4 million in 2023, then surged by 123.91% to $3.1 million in 2024, then surged by 30.22% to $4.1 million in 2025.
  • Its Change in Inventory was $4.1 million in Q3 2025, compared to $7.6 million in Q2 2025 and $3.6 million in Q1 2025.